Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update [0.03%]
2020-2022年神经生长因子受体-Trk类型I抑制剂专利分析更新研究报告
Carolin Jaworski,Petar Iliev,Carmen Wängler et al.
Carolin Jaworski et al.
Introduction: Trk inhibitors are significant in the realm of personalized medicine as they target specific genetic alterations, such as NTRK gene fusions, leading to improved treatment outcomes for cancer patients. By tai...
Targeting carbonic anhydrases for the management of hypoxic metastatic tumors [0.03%]
靶向碳酸酐酶以管理低氧转移性肿瘤
Claudiu T Supuran
Claudiu T Supuran
Introduction: Several isoforms of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) are connected with tumorigenesis. Hypoxic tumors overexpress CA IX and XII as a consequence of HIF activation cascade, being involved...
Patent landscape highlighting therapeutic implications of peptides targeting myristoylated alanine-rich protein kinase-C substrate (MARCKS) [0.03%]
靶向肌尾蛋白(MARCKS)的肽的治疗意义的专利布局分析
Vikas Yadav,Amarish Kumar Sharma,Gaurav Parashar et al.
Vikas Yadav et al.
Introduction: MARCKS protein, a protein kinase C (PKC) substrate, is known to be at the intersection of several intracellular signaling pathways and plays a pivotal role in cellular physiology. Unlike PKC inhibitors, MARC...
Valentin R Wydra,Raphael B Ditzinger,Nico J Seidler et al.
Valentin R Wydra et al.
Introduction: The mitogen-activated protein kinase (MAPK) family consist of p38 MAP kinases, c-Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs). They are involved in a multitude of diseases,...
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review [0.03%]
用于慢性髓性白血病的BCR-ABL靶向蛋白降解嵌合体(PROTACs)治疗的专利回顾
André T S Vicente,Jorge A R Salvador
André T S Vicente
Introduction: PROteolysis-TArgeting Chimeras (PROTACs) allow the selective degradation of a protein of interest (POI) by the ubiquitin-proteasome system (UPS). With this unique mechanism of action, the research and develo...
Yiming Xu,Savannah Biby,Baljit Kaur et al.
Yiming Xu et al.
Introduction: NOD-like receptor family pyrin domain containing 3 (NLRP3) can sense a plethora of exogenous and endogenous dangers. Upon activation, a multimeric protein complex, the NLRP3 inflammasome, is formed to initia...
Jingjing Liu,Fangkui Yin,Ziqian Wang et al.
Jingjing Liu et al.
Introduction: Myeloid leukemia 1 (Mcl-1), an antiapoptotic protein of the Bcl-2 family, is an attractive target for cancer therapy. In recent years, significant progress has been made with regard to Mcl-1 inhibitors, lead...
Cătălin Constantinescu,Roxana Constantinescu,Jon Thor Bergthorsson et al.
Cătălin Constantinescu et al.
Introduction: Emerging immunotherapies are pushing the boundaries of cancer treatment, with chimeric antigen receptor (CAR)-T cell therapy being one of the most advanced. Due to the increasingly crowded CAR-T cell field, ...
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present) [0.03%]
2020年以来组蛋白去乙酰化酶（HDAC）抑制剂在癌症治疗领域专利现状分析
Yi-Min Liu,Jing-Ping Liou
Yi-Min Liu
Introduction: Histone deacetylase (HDAC) inhibitors have been considered as an attractive strategy to reverse aberrant epigenetic changes associated with cancer treatments. The use of HDAC inhibitors in various cancer typ...
Ferenc Baska,Éva Bozó,Tamás Patócs
Ferenc Baska
Introduction: Arginine-vasopressin hormone (AVP) is a key regulator in many essential physiological processes. The effect of AVP is mediated through three receptors within the body, these are the G protein-coupled vasopre...